Literature DB >> 30509966

Associations of tumor necrosis factor-α polymorphisms with the risk of colorectal cancer: a meta-analysis.

Xue Huang1, Shanyu Qin1, Yongru Liu1, Lin Tao1, Haixing Jiang2.   

Abstract

Background: Recently, the roles of tumor necrosis factor-α (TNF-α) polymorphisms in colorectal cancer (CRC) were analyzed by some pilot studies, with inconsistent results. Therefore, we performed the present study to better assess the relationship between TNF-α polymorphisms and the risk of CRC.
Methods: Eligible studies were searched in PubMed, Medline, Embase and CNKI. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess correlations between TNF-α polymorphisms and CRC.
Results: A total of 22 studies were included for analyses. A significant association with the risk of CRC was detected for TNF-308 G/A (recessive model: P = 0.004, OR = 1.42, 95%CI 1.12-1.79) polymorphism in overall analyses. Further subgroup analyses based on ethnicity of participants revealed that TNF-238 G/A was significantly correlated with the risk of CRC in Caucasians (dominant model: P = 0.01, OR = 0.47, 95%CI 0.26-0.86; overdominant model: P = 0.01, OR = 2.27, 95%CI 1.20-4.30; allele model: P = 0.02, OR = 0.51, 95%CI 0.29-0.90), while -308 G/A polymorphism was significantly correlated with the risk of CRC in Asians (recessive model: P = 0.001, OR = 2.23, 95%CI 1.38-3.63).Conclusions: Our findings indicated that TNF-238 G/A polymorphism may serve as a potential biological marker for CRC in Caucasians, and TNF-308 G/A polymorphism may serve as a potential biological marker for CRC in Asians.
© 2019 The Author(s).

Entities:  

Keywords:  Colorectal cancer (CRC); Gene polymorphisms; Meta-analysis; Tumor necrosis factor-α (TNF-α)

Mesh:

Substances:

Year:  2019        PMID: 30509966      PMCID: PMC6328862          DOI: 10.1042/BSR20181750

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


Introduction

Colorectal cancer (CRC) refers to malignancy that occurs in the colon and rectum. It is the third most commonly seen cancer in men, and the second commonly seen cancer in women [1]. Despite rapid advances in early diagnosis and surgical treatment over the past few decades, CRC still accounts for approximately one-tenth of cancer-related deaths, making it one of the major threats to public health worldwide [2]. To date, the exact cause of CRC remains unclear. Although smoking, excessive alcohol intake and high consumption of red meat were already identified as potential risk factors of CRC [3-5]. The fact that a significant portion of CRC patients did not expose to any of these carcinogenic factors suggests that genetic susceptibility may play a crucial part in the pathogenesis of CRC [6]. Tumor necrosis factor-α (TNF-α) plays a central role in the regulation of anti-tumor immune responses. Previous clinical investigations showed that serum TNF-α levels in CRC patients were significantly elevated [7], and patients with lower TNF-α levels had better prognosis compared with these with higher TNF-α levels [8,9]. Consequently, functional TNF-α polymorphisms were thought to be ideal candidate genetic markers of CRC. Recently, some pilot studies were conducted to investigate associations between TNF-α polymorphisms and the risk of CRC. But the results of these studies were conflicting [10-31]. Therefore, we conducted this meta-analysis to better analyze the roles of TNF-α polymorphisms in the development of CRC.

Materials and methods

Literature search and inclusion criteria

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [32]. Potentially eligible articles were searched in PubMed, Medline, Embase and CNKI using the combination of following key words: ‘tumor necrosis factor-α’, ‘TNF-α’, ‘polymorphism’, ‘variant’, ‘mutation’, ‘genotype’, ‘allele’, ‘colorectal’, ‘colon’, ‘rectal’, ‘cancer’, ‘tumor’, ‘carcinoma’, ‘neoplasm’ and ‘malignancy’. The initial literature search was conducted in 2018 February and the latest update was performed in 2018 July. The reference lists of all retrieved publications were also screened to identify other potentially relevant articles. Included studies should meet all the following criteria: (1) case–control study on correlations between TNF-α polymorphisms and the risk of CRC; (2) provide adequate data to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (3) full text available. Studies were excluded if one of the following criteria was fulfilled: (1) not relevant to TNF-α polymorphisms and CRC; (2) family-based association studies; (3) case reports or case series; (4) abstracts, reviews, comments, letters and conference presentations. For duplicate reports, only the study with the largest sample size was included. No language restrictions were imposed in this meta-analysis.

Data extraction and quality assessment

The following data were extracted from included studies: (1) name of the first author; (2) year of publication; (3) country and ethnicity of participants; (4) the number of cases and controls and (5) genotypic distributions of TNF-α polymorphisms in cases and controls. Additionally, the probability value (P value) of Hardy–Weinberg equilibrium (HWE) test was also calculated based on genotypic frequency of TNF-α polymorphisms in the control group. The Newcastle–Ottawa scale (NOS) was employed to assess the quality of eligible studies from three aspects: (1) selection of cases and controls; (2) comparability between cases and controls and (3) exposure in cases and controls [33]. The NOS has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality. Two reviewers (Huang and Qin) conducted data extraction and quality assessment independently. When necessary, the reviewers wrote to the corresponding authors for extra information or raw data. Any disagreement between two reviewers was solved by discussion with the third reviewer (Jiang) until a consensus was reached.

Statistical analyses

All statistical analyses in the present study were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). ORs and 95% CIs were used to assess potential associations of TNF-α polymorphisms with the risk of CRC in the dominant, recessive, overdominant and allele models, and a P value of 0.05 or less was considered to be statistically significant. Between-study heterogeneity was evaluated based on Q test and I2 statistic. If P value of Q test was less than 0.1 or I2 was greater than 50%, random-effect models (REMs) would be used for analyses due to the existence of significant heterogeneities. Otherwise, fixed-effect models (FEMs) would be applied for analyses. Subgroup analyses by ethnicity of participants were subsequently conducted to obtain more specific results. Sensitivity analyses were carried out to test the stability of the results. Funnel plots were applied to evaluate possible publication bias.

Results

Characteristics of included studies

The literature search identified 389 potentially relevant articles. After exclusion of irrelevant and duplicate articles by reading titles and abstracts, 42 articles were retrieved for further evaluation. Another 20 articles were subsequently excluded after reading the full text. Finally, a total of 22 eligible studies were included in this meta-analysis (see Figure 1). Characteristics of included studies were summarized in Table 1.
Figure 1

Flowchart of study selection for the present study

Table 1

The characteristics of included studies for TNF-α polymorphisms and CRC

First author, yearCountryEthnicitySource of controlsSample sizeGenotype distributionP-value for HWENOS score
CasesControls
-238 G/AGG/GA/AA
Garrity-Park 2008 [13]USAMixedHB114/114109/5/0107/6/10.0178
Gutiérrez-Hurtado 2016 [15]MexicoMixedPB143/49127/14/242/6/10.1997
Hamadien 2016 [16]Saudi ArabiaCaucasianPB100/10086/13/197/2/1<0.0018
Jang 2001 [17]KoreaAsianPB27/9227/0/080/11/10.3918
Kapitanović 2014 [18]CroatiaCaucasianPB200/200181/18/1188/11/10.0768
Madani 2008 [24]IranCaucasianPB51/4651/0/045/1/00.9417
Wang 2008 [31]ChinaAsianPB343/670320/22/1620/50/00.3168
-308 G/AGG/GA/AA
Banday 2016 [10]IndiaCaucasianPB142/184124/18/0150/34/00.1678
Basavaraju 2015 [11]UKCaucasianPB388/495253/117/18309/167/190.5437
Burada 2013 [12]RomaniaCaucasianPB144/233115/26/3189/42/20.8428
Garrity-Park 2008 [13]USAMixedHB114/11452/49/1392/20/20.4648
Gunter 2006 [14]USAMixedPB217/202146/59/12139/57/60.9578
Gutiérrez-Hurtado 2016 [15]MexicoMixedPB164/209139/21/4180/27/20.3927
Hamadien 2016 [16]Saudi ArabiaCaucasianPB100/10067/23/1059/23/18<0.0018
Jang 2001 [17]KoreaAsianPB27/9224/3/085/7/00.7048
Kapitanović 2014 [18]CroatiaCaucasianPB200/200163/35/2163/35/20.9378
Landi 2003 [19]FranceCaucasianPB363/320278/80/5234/76/100.2207
Li 2011 [21]ChinaAsianPB180/180156/15/9160/19/10.5998
Li 2017 [22]ChinaAsianPB569/570500/66/3493/75/20.6328
Macarthur 2005 [23]UKCaucasianPB246/389157/74/15224/145/200.5778
Park 1998 [25]KoreaAsianPB136/33140/71/25148/151/320.4657
Stanilov 2014 [26]BulgariaCaucasianPB119/17788/28/3135/40/20.6128
Suchy 2008 [27]PolandCaucasianPB350/350254/87/9248/95/70.5468
Theodoropoulos 2006 [28]GreeceCaucasianPB222/200152/56/14146/44/100.0107
Toth 2007 [29]HungaryCaucasianPB183/141132/48/3111/30/00.1577
Tsilidis 2009 [30]USAMixedPB204/372146/55/3275/90/70.9087
Wang 2008 [31]ChinaAsianPB344/669284/58/2554/111/40.5388
-857 C/TCC/CT/TT
Garrity-Park 2008 [13]USAMixedHB114/11498/16/092/22/00.2548
Hamadien 2016 [16]Saudi ArabiaCaucasianPB100/10085/15/085/15/00.4178
Kapitanović 2014 [18]CroatiaCaucasianPB200/200130/64/6126/67/70.5998
Landi 2006 [20]SpainCaucasianPB281/268219/58/4220/45/30.6847
Suchy 2008 [27]PolandCaucasianPB350/350253/88/9242/98/100.9838
-863 C/ACC/CA/AA
Garrity-Park 2008 [13]USAMixedHB114/11484/28/280/33/10.2248
Suchy 2008 [27]PolandCaucasianPB350/350262/77/11257/83/100.3028
-1031 T/CTT/TC/CC
Garrity-Park 2008 [13]USAMixedHB114/11479/31/475/36/30.5888
Kapitanović 2014 [18]CroatiaCaucasianPB200/200132/56/12135/54/110.0828
Suchy 2008 [27]PolandCaucasianPB350/350250/90/10227/107/160.4608

Abbreviations: CRC, colorectal cancer; HWE, Hardy–Weinberg equilibrium; NA, not available; NOS, Newcastle–Ottawa scale; TNF-α, tumor necrosis factor-α.

Abbreviations: CRC, colorectal cancer; HWE, Hardy–Weinberg equilibrium; NA, not available; NOS, Newcastle–Ottawa scale; TNF-α, tumor necrosis factor-α.

Overall and subgroup analyses

To investigate potential correlations of TNF-α polymorphisms with the risk of CRC, 7 studies about TNF-238 G/A polymorphism (901 cases and 1179 controls), 20 studies about TNF-308 G/A polymorphism (4412 cases and 5528 controls), 5 studies about TNF-857 C/T polymorphism (1045 cases and 1032 controls), 2 studies about TNF-863 C/A polymorphism (464 cases and 464 controls) and 3 studies about TNF-1031 T/C polymorphism (664 cases and 664 controls) were enrolled for analyses. A significant association with the risk of CRC was detected for TNF-308 G/A (recessive model: P = 0.004, OR = 1.42, 95%CI 1.12–1.79) polymorphism in overall analyses. Further subgroup analyses based on ethnicity of participants revealed that TNF-238 G/A was significantly correlated with the risk of CRC in Caucasians (dominant model: P = 0.01, OR = 0.47, 95%CI 0.26–0.86; overdominant model: P = 0.01, OR = 2.27, 95%CI 1.20–4.30; allele model: P = 0.02, OR = 0.51, 95%CI 0.29–0.90), while -308 G/A polymorphism was significantly correlated with the risk of CRC in Asians (recessive model: P = 0.001, OR = 2.23, 95%CI 1.38–3.63). No any other positive results were found for investigated polymorphisms in overall and subgroup analyses (see Table 2).
Table 2

Overall and subgroup analyses for TNF-α polymorphisms and CRC

PolymorphismsPopulationSample sizeDominant comparisonRecessive comparisonOverdominant comparisonAllele comparison
P valueOR (95%CI)P valueOR (95%CI)P valueOR (95%CI)P valueOR (95%CI)
-238 G/AOverall901/11790.720.94 (0.68–1.31)0.941.04 (0.34–3.20)0.681.07 (0.77-1.51)0.770.95 (0.70–1.31)
Caucasian351/3460.010.47 (0.26–0.86)1.001.00 (0.14–7.15)0.012.27 (1.20-4.30)0.020.51 (0.29–0.90)
Asian370/7620.311.29 (0.79–2.12)0.342.69 (0.35–20.78)0.260.75 (0.45–1.24)0.381.24 (0.77–2.00)
-308 G/AOverall4412/55280.300.92 (0.78–1.08)0.0041.42 (1.12–1.79)0.840.99 (0.90–1.09)0.170.90 (0.77–1.05)
Caucasian2457/27890.211.08 (0.96–1.22)0.761.05 (0.77–1.42)0.150.91 (0.80–1.03)0.321.06 (0.95–1.17)
Asian4412/55280.270.83 (0.60–1.15)0.0012.23 (1.38–3.63)0.901.01 (0.83–1.24)0.160.81 (0.60–1.09)
-857 C/TOverall1045/10320.621.05 (0.86–1.28)0.850.94 (0.50–1.78)0.660.95 (0.78–1.17)0.621.05 (0.87–1.25)
Caucasian931/9180.851.02 (0.83–1.26)0.850.94 (0.50–1.78)0.890.99 (0.80–1.22)0.821.02 (0.85–1.23)
-863 C/AOverall464/4640.501.11 (0.83–1.48)0.681.19 (0.53–2.68)0.400.88 (0.65–1.19)0.641.06 (0.82–1.38)
-1031 T/COverall664/6640.161.18 (0.94–1.48)0.580.86 (0.50–1.47)0.220.86 (0.68–1.09)0.161.15 (0.95–1.40)
Caucasian550/5500.201.18 (0.92–1.52)0.470.81 (0.45–1.44)0.310.87 (0.67–1.14)0.171.16 (0.94–1.44)

Abbreviations: CI, confidence interval; CRC, colorectal cancer; NA, not available; OR, odds ratio; TNF-α, tumor necrosis factor-α.

For -238 G/A, Dominant comparison: G/A + A/A vs. G/G; Recessive comparison: A/A vs. G/G + G/A; Overdominant comparison: G/G + A/A vs. G/A; Allele comparison: G vs. A.

For -308 G/A, Dominant comparison: G/A + A/A vs. G/G; Recessive comparison: A/A vs. G/G + G/A; Overdominant comparison: G/G + A/A vs. G/A; Allele comparison: G vs. A.

For -857 C/T, Dominant comparison: C/T + T/T vs. C/C; Recessive comparison: T/T vs. C/C + C/T; Overdominant comparison: C/C + T/T vs. C/T; Allele comparison: C vs. T.

For -863 C/A, Dominant comparison: C/A + A/A vs. C/C; Recessive comparison: A/A vs. C/C + C/A; Overdominant comparison: C/C + A/A vs. C/A; Allele comparison: C vs. A.

For -1031 T/C, Dominant comparison: T/C + C/C vs. T/T; Recessive comparison: C/C vs. T/T + T/C; Overdominant comparison: T/T + C/C vs. T/C; Allele comparison: T vs. C.

Abbreviations: CI, confidence interval; CRC, colorectal cancer; NA, not available; OR, odds ratio; TNF-α, tumor necrosis factor-α. For -238 G/A, Dominant comparison: G/A + A/A vs. G/G; Recessive comparison: A/A vs. G/G + G/A; Overdominant comparison: G/G + A/A vs. G/A; Allele comparison: G vs. A. For -308 G/A, Dominant comparison: G/A + A/A vs. G/G; Recessive comparison: A/A vs. G/G + G/A; Overdominant comparison: G/G + A/A vs. G/A; Allele comparison: G vs. A. For -857 C/T, Dominant comparison: C/T + T/T vs. C/C; Recessive comparison: T/T vs. C/C + C/T; Overdominant comparison: C/C + T/T vs. C/T; Allele comparison: C vs. T. For -863 C/A, Dominant comparison: C/A + A/A vs. C/C; Recessive comparison: A/A vs. C/C + C/A; Overdominant comparison: C/C + A/A vs. C/A; Allele comparison: C vs. A. For -1031 T/C, Dominant comparison: T/C + C/C vs. T/T; Recessive comparison: C/C vs. T/T + T/C; Overdominant comparison: T/T + C/C vs. T/C; Allele comparison: T vs. C.

Sensitivity analyses

Sensitivity analyses were carried out to examine the stability of meta-analysis results by eliminating studies that deviated from HWE. No changes of results were observed in any comparisons, which indicated that our findings were statistically reliable.

Publication biases

Potential publication biases in the current study were evaluated with funnel plots. No obvious asymmetry of funnel plots was observed in any comparisons, which suggested that our findings were unlikely to be influenced by severe publication biases.

Discussion

To the best of our knowledge, this is so far the most comprehensive meta-analysis on correlations between TNF-α polymorphisms and CRC. A significant association with the risk of CRC was detected for TNF-308 G/A polymorphism in overall analyses. Further subgroup analyses based on ethnicity of participants revealed that TNF-238 G/A was significantly correlated with the risk of CRC in Caucasians, while -308 G/A polymorphism was significantly correlated with the risk of CRC in Asians. No any other positive results were found for investigated polymorphisms in overall and subgroup analyses. The stability of the synthetic results was subsequently evaluated in sensitivity analyses, and no changes of results were observed in any comparisons, which indicated that our findings were quite stable and reliable. It is worth noting that -238 G/A and -308 G/A polymorphisms were two functional polymorphisms located in the promoter region of TNF-α, and the mutant alleles of these two polymorphisms were both associated with a higher expression level of TNF-α [10-15]. Thus, it is rational to speculate that subjects carrying mutant alleles of these two polymorphisms may have a relatively lower risk of CRC. From our results, you can see that the trends of developing CRC for these two polymorphisms in overall population are quite similar. But opposite findings were detected in further subgroup analyses. These contradictory findings in subgroup analyses may partially attribute to quite different genetics distributions of these two polymorphisms in Asians and Caucasians. Another possible explanation of this phenomenon is that genetic associations between TNF-α polymorphisms and CRC may also be influenced by gene-gene and gene-environmental interactions, but the extent of impact of gene–gene and gene–environmental interactions on genetic association between TNF-α polymorphisms and CRC in different ethnicities may be different. As for evaluation of heterogeneities, obvious between-study heterogeneities were detected for -308 G/A polymorphisms in certain comparisons (data not shown). In further stratified analyses, a great reduction in heterogeneity was found in the Asian subgroup. However, the reduction tendency of heterogeneity in Caucasians was not obvious. These findings suggested that differences in ethnic background could partially explain observed heterogeneities between studies. As with all meta-analysis, the present study certainly has some limitations. First, our results were based on unadjusted estimations due to lack of raw data, and failure to perform further stratified analyses according to age, gender and co-morbidity conditions may affect the reliability of our findings [34,35]. Second, only case-control studies were included in this meta-analysis, and thus our findings may also be influenced by potential selection bias [35,36]. Third, associations between TNF-α polymorphisms and CRC may also be influenced by gene-gene and gene-environmental interactions. However, the majority of studies did not consider these potential interactions, which impeded us to perform relevant analyses accordingly [37,38]. Taken these limitations into consideration, the results of the current study should be interpreted with caution. Overall, our meta-analysis suggested that TNF-238 G/A polymorphism may serve as a potential biological marker for CRC in Caucasians, and TNF-308 G/A polymorphism may serve as a potential biological marker for CRC in Asians. However, further well-designed studies are warranted to confirm our findings. Additionally, future investigations are needed to explore potential roles of other TNF-α polymorphisms in the development of CRC.
  35 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

3.  Endothelial nitric oxide synthase gene single nucleotide polymorphisms and the risk of hypertension: A meta-analysis involving 63,258 subjects.

Authors:  Xiaochuan Xie; Xiaohan Shi; Xiaoshuang Xun; Li Rao
Journal:  Clin Exp Hypertens       Date:  2017-03-01       Impact factor: 1.749

4.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

5.  Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer.

Authors:  Stefano Landi; Victor Moreno; Lydie Gioia-Patricola; Elisabeth Guino; Matilde Navarro; Javier de Oca; Gabriel Capella; Federico Canzian
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

Review 6.  Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis.

Authors:  Peter S Liang; Ting-Yi Chen; Edward Giovannucci
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

Review 7.  The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects.

Authors:  Yu Liu; Jianxin Cheng; Xiangyi Guo; Jingjing Mo; Beibei Gao; Huiyuan Zhou; Yixin Wu; Zhijuan Li
Journal:  Gene       Date:  2018-06-22       Impact factor: 3.688

8.  Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies.

Authors:  Doris S M Chan; Rosa Lau; Dagfinn Aune; Rui Vieira; Darren C Greenwood; Ellen Kampman; Teresa Norat
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

9.  Polymorphisms within inflammatory genes and colorectal cancer.

Authors:  Stefano Landi; Federica Gemignani; Fabio Bottari; Lydie Gioia-Patricola; Elisabet Guino; María Cambray; Sebastiano Biondo; Gabriel Capella; Laura Boldrini; Federico Canzian; Victor Moreno
Journal:  J Negat Results Biomed       Date:  2006-10-24

10.  Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk.

Authors:  Janina Suchy; Ewa Kłujszo-Grabowska; Józef Kładny; Cezary Cybulski; Dominika Wokołorczyk; Jolanta Szymańska-Pasternak; Grzegorz Kurzawski; Rodney J Scott; Jan Lubiński
Journal:  BMC Cancer       Date:  2008-04-23       Impact factor: 4.430

View more
  4 in total

1.  rs401502 and rs11575934 Polymorphisms of the IL-12 Receptor Beta 1 Gene are Protective Against Colorectal Carcinogenesis.

Authors:  Refka Jelassi; Sabrine Dhouioui; Hamza Ben Salah; Nasreddine Saidi; Nabiha Mzoughi; Radhia Ammi; Aida Bouratbine; Karim Aoun; Ines Zidi; Hanen Chelbi
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

Review 2.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09

3.  Association between pre-diagnostic circulating adipokines and colorectal cancer and adenoma in the CLUE II cohort.

Authors:  Michael T Marrone; Jiayun Lu; Kala Visvanathan; Corinne E Joshu; Elizabeth A Platz
Journal:  Cancer Causes Control       Date:  2021-05-17       Impact factor: 2.532

4.  A Network Pharmacology Approach to Explore the Potential Mechanisms of Huangqin-Baishao Herb Pair in Treatment of Cancer.

Authors:  Tian Xu; Qingguo Wang; Min Liu
Journal:  Med Sci Monit       Date:  2020-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.